Digistain has been nominated for the EIT Awards 2026 in the Venture Award category. The Venture Award recognises organisations combining strong commercial potential with meaningful real-world impact. For us, that means working towards more accessible, personalised cancer care, so that every patient can benefit from better-informed treatment decisions.
The nomination follows our selection in September 2025 as winners of the 2025 EIT Health Open Innovation Breast Cancer Challenge, by a panel of judges from EIT Health, AstraZeneca Spain, SERMAS and Hospital 12 de Octubre. As part of that prize, Hospital 12 de Octubre was named as the first site in Spain where patients can benefit from Digistain.
Thank you to EIT, the European Institute of Innovation and Technology, and especially EIT Health, for their continued support.
